Management of comorbid bipolar disorder and substance use disorders

Ihsan M Salloum, Edson Sherwood Brown

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

Background: The comorbidity of substance use disorders (SUDs) in bipolar disorder is among the highest in psychiatric disorders. Evidence-based controlled psychosocial or pharmacological interventions trials, which may guide treatment decisions, have not been systematically reviewed. Objective: To present a narrative review of the public health and clinical significance of this condition, including diagnostic and treatment implications, and to evaluate controlled trials conducted to date. Methods: Controlled trials reports in the English language were identified from multiple electronic databases and hand-searching bibliographies. We searched for treatment studies of bipolar disorder and comorbid SUDs (alcohol, cocaine, stimulants, opioid, tobacco, cannabis). Search period included all reports through September of 2016. We selected only randomized psychosocial studies or double-blind, placebo-controlled pharmacotherapy trials. We also reviewed reports of the public health and clinical significance and principle of managements of this condition. Results: We identified 16 treatment studies: 3 psychotherapy, and 13 pharmacotherapy trials. The following medications were evaluated: lithium carbonate, valproate, lamotrigine, topiramate, naltrexone, acamprosate, disulfiram, quetiapine, and citicoline. SUDs have substantial impact on the recognition and management of bipolar disorder. Integrated psychosocial interventions are helpful in decreasing substance abuse. Valproate and naltrexone may decrease alcohol use and citicoline may decrease cocaine use and enhance cognition. Conclusions: There is a very limited number of pharmacotherapy and an even smaller number of psychosocial interventions. Our review highlights the need for more research in this area and for larger, multisite studies with generalizable samples to provide more definite guidance for clinical practice.

Original languageEnglish (US)
Pages (from-to)366-376
Number of pages11
JournalAmerican Journal of Drug and Alcohol Abuse
Volume43
Issue number4
DOIs
StatePublished - Jul 4 2017

Fingerprint

Bipolar Disorder
Substance-Related Disorders
Cytidine Diphosphate Choline
Naltrexone
Valproic Acid
Cocaine
Drug Therapy
Public Health
Alcohols
Lithium Carbonate
Disulfiram
Bibliography
Therapeutics
Cannabis
Double-Blind Method
Psychotherapy
Cognition
Opioid Analgesics
Tobacco
Psychiatry

Keywords

  • Alcohol use disorder
  • bipolar disorder
  • clinical trials
  • comorbidity
  • dual diagnosis
  • substance use disorders

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Clinical Psychology
  • Psychiatry and Mental health

Cite this

Management of comorbid bipolar disorder and substance use disorders. / Salloum, Ihsan M; Brown, Edson Sherwood.

In: American Journal of Drug and Alcohol Abuse, Vol. 43, No. 4, 04.07.2017, p. 366-376.

Research output: Contribution to journalReview article

@article{45deb64ac625463d8b5ac7682362b8e9,
title = "Management of comorbid bipolar disorder and substance use disorders",
abstract = "Background: The comorbidity of substance use disorders (SUDs) in bipolar disorder is among the highest in psychiatric disorders. Evidence-based controlled psychosocial or pharmacological interventions trials, which may guide treatment decisions, have not been systematically reviewed. Objective: To present a narrative review of the public health and clinical significance of this condition, including diagnostic and treatment implications, and to evaluate controlled trials conducted to date. Methods: Controlled trials reports in the English language were identified from multiple electronic databases and hand-searching bibliographies. We searched for treatment studies of bipolar disorder and comorbid SUDs (alcohol, cocaine, stimulants, opioid, tobacco, cannabis). Search period included all reports through September of 2016. We selected only randomized psychosocial studies or double-blind, placebo-controlled pharmacotherapy trials. We also reviewed reports of the public health and clinical significance and principle of managements of this condition. Results: We identified 16 treatment studies: 3 psychotherapy, and 13 pharmacotherapy trials. The following medications were evaluated: lithium carbonate, valproate, lamotrigine, topiramate, naltrexone, acamprosate, disulfiram, quetiapine, and citicoline. SUDs have substantial impact on the recognition and management of bipolar disorder. Integrated psychosocial interventions are helpful in decreasing substance abuse. Valproate and naltrexone may decrease alcohol use and citicoline may decrease cocaine use and enhance cognition. Conclusions: There is a very limited number of pharmacotherapy and an even smaller number of psychosocial interventions. Our review highlights the need for more research in this area and for larger, multisite studies with generalizable samples to provide more definite guidance for clinical practice.",
keywords = "Alcohol use disorder, bipolar disorder, clinical trials, comorbidity, dual diagnosis, substance use disorders",
author = "Salloum, {Ihsan M} and Brown, {Edson Sherwood}",
year = "2017",
month = "7",
day = "4",
doi = "10.1080/00952990.2017.1292279",
language = "English (US)",
volume = "43",
pages = "366--376",
journal = "American Journal of Drug and Alcohol Abuse",
issn = "0095-2990",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Management of comorbid bipolar disorder and substance use disorders

AU - Salloum, Ihsan M

AU - Brown, Edson Sherwood

PY - 2017/7/4

Y1 - 2017/7/4

N2 - Background: The comorbidity of substance use disorders (SUDs) in bipolar disorder is among the highest in psychiatric disorders. Evidence-based controlled psychosocial or pharmacological interventions trials, which may guide treatment decisions, have not been systematically reviewed. Objective: To present a narrative review of the public health and clinical significance of this condition, including diagnostic and treatment implications, and to evaluate controlled trials conducted to date. Methods: Controlled trials reports in the English language were identified from multiple electronic databases and hand-searching bibliographies. We searched for treatment studies of bipolar disorder and comorbid SUDs (alcohol, cocaine, stimulants, opioid, tobacco, cannabis). Search period included all reports through September of 2016. We selected only randomized psychosocial studies or double-blind, placebo-controlled pharmacotherapy trials. We also reviewed reports of the public health and clinical significance and principle of managements of this condition. Results: We identified 16 treatment studies: 3 psychotherapy, and 13 pharmacotherapy trials. The following medications were evaluated: lithium carbonate, valproate, lamotrigine, topiramate, naltrexone, acamprosate, disulfiram, quetiapine, and citicoline. SUDs have substantial impact on the recognition and management of bipolar disorder. Integrated psychosocial interventions are helpful in decreasing substance abuse. Valproate and naltrexone may decrease alcohol use and citicoline may decrease cocaine use and enhance cognition. Conclusions: There is a very limited number of pharmacotherapy and an even smaller number of psychosocial interventions. Our review highlights the need for more research in this area and for larger, multisite studies with generalizable samples to provide more definite guidance for clinical practice.

AB - Background: The comorbidity of substance use disorders (SUDs) in bipolar disorder is among the highest in psychiatric disorders. Evidence-based controlled psychosocial or pharmacological interventions trials, which may guide treatment decisions, have not been systematically reviewed. Objective: To present a narrative review of the public health and clinical significance of this condition, including diagnostic and treatment implications, and to evaluate controlled trials conducted to date. Methods: Controlled trials reports in the English language were identified from multiple electronic databases and hand-searching bibliographies. We searched for treatment studies of bipolar disorder and comorbid SUDs (alcohol, cocaine, stimulants, opioid, tobacco, cannabis). Search period included all reports through September of 2016. We selected only randomized psychosocial studies or double-blind, placebo-controlled pharmacotherapy trials. We also reviewed reports of the public health and clinical significance and principle of managements of this condition. Results: We identified 16 treatment studies: 3 psychotherapy, and 13 pharmacotherapy trials. The following medications were evaluated: lithium carbonate, valproate, lamotrigine, topiramate, naltrexone, acamprosate, disulfiram, quetiapine, and citicoline. SUDs have substantial impact on the recognition and management of bipolar disorder. Integrated psychosocial interventions are helpful in decreasing substance abuse. Valproate and naltrexone may decrease alcohol use and citicoline may decrease cocaine use and enhance cognition. Conclusions: There is a very limited number of pharmacotherapy and an even smaller number of psychosocial interventions. Our review highlights the need for more research in this area and for larger, multisite studies with generalizable samples to provide more definite guidance for clinical practice.

KW - Alcohol use disorder

KW - bipolar disorder

KW - clinical trials

KW - comorbidity

KW - dual diagnosis

KW - substance use disorders

UR - http://www.scopus.com/inward/record.url?scp=85020452794&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020452794&partnerID=8YFLogxK

U2 - 10.1080/00952990.2017.1292279

DO - 10.1080/00952990.2017.1292279

M3 - Review article

C2 - 28301219

AN - SCOPUS:85020452794

VL - 43

SP - 366

EP - 376

JO - American Journal of Drug and Alcohol Abuse

JF - American Journal of Drug and Alcohol Abuse

SN - 0095-2990

IS - 4

ER -